Publications by authors named "Samuel Truniger"

Claim this Profile
F
First Description of Upadacitinib as Treatment for Collagenous Colitis with a Concomitant Lymphocytic Disorder of the Upper Gastrointestinal Tract.
Samuel Truniger, Jan Borovicka, Marius König, Michael Bento Schmid, Nicola Fabian Frei

Case Rep Gastroenterol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XBB.1.5 COVID-19 mRNA Vaccines Induce Inadequate Mucosal Immunity in Patients with Inflammatory Bowel Disease.
Simon Woelfel, Joel Dütschler, Daniel Junker, Marius König, Georg Leinenkugel, Samuel Truniger

Vaccines (Basel)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First Description of Simultaneous Sweet Syndrome and Tracheal Stenosis as Extraintestinal Manifestations in a Patient With Highly Active Ulcerative Colitis.
Hala Alrasheed, Oray Kahraman, Eva Markert, Olaf Chan-Hi Kim, Christin Pelzer, Samuel Truniger

ACG Case Rep J· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease.
Simon Woelfel, Joel Dütschler, Daniel Junker, Marius König, Nicole Graf, Samuel Truniger

Aliment Pharmacol Ther· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver Disease.
Simon Woelfel, Daniel Junker, Irina Bergamin, Pamela Meyer-Herbon, Roman Stillhard, Samuel Truniger

Vaccines (Basel)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5-Adapted COVID-19 mRNA Vaccines in Patients with Inflammatory Bowel Disease.
Simon Woelfel, Joel Dütschler, Daniel Junker, Marius König, Georg Leinenkugel, Samuel Truniger

Vaccines (Basel)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Modern endoscopy in inflammatory bowel disease].
Samuel Truniger, Remus Frei, Stephan Brand

Ther Umsch· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.
Simon Woelfel, Joel Dütschler, Marius König, Alex Dulovic, Nicole Graf, Samuel Truniger

Aliment Pharmacol Ther· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
Simon Woelfel, Joel Dütschler, Marius König, Nicole Graf, Vasileios Oikonomou, Samuel Truniger

Aliment Pharmacol Ther· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a uniform, very aggressive disease phenotype in all homozygous carriers of the NOD2 mutation p.Leu1007fsX1008 with Crohn's disease and active smoking status resulting in ileal stenosis requiring surgery.
Fabian Schnitzler, Matthias Friedrich, Marianne Angelberger, Julia Diegelmann, Johannes Stallhofer, Samuel Truniger

PLoS One· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis